The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case-control study
EU-GEI WP2 Group
(2023) Social Psychiatry and Psychiatric Epidemiology, volume 58, issue 10, pp. 1573 - 1580
(Article)
Abstract
This study investigated if the association between childhood maltreatment and cognition among psychosis patients and community controls was partially accounted for by genetic liability for psychosis. Patients with first-episode psychosis (N = 755) and unaffected controls (N = 1219) from the EU-GEI study were assessed for childhood maltreatment, intelligence quotient (IQ), family history of
... read more
psychosis (FH), and polygenic risk score for schizophrenia (SZ-PRS). Controlling for FH and SZ-PRS did not attenuate the association between childhood maltreatment and IQ in cases or controls. Findings suggest that these expressions of genetic liability cannot account for the lower levels of cognition found among adults maltreated in childhood.
show less
Download/Full Text
Keywords: Childhood adversity, Cognition, Family history of psychosis, First episode, Polygenic risk score, Psychosis, Health(social science), Psychiatry and Mental health, Social Psychology, Epidemiology, Journal Article
ISSN: 0933-7954
Publisher: D. Steinkopff-Verlag
Note: Funding Information: We are grateful to the EU-GEI study participants for their essential contribution to this project. The EU-GEI Study is funded by grant agreement HEALTH-F2-2010–241909 (Project EU-GEI) from the European Community’s Seventh Framework Programme, and Grant 2012/0417–0 from the São Paulo Research Foundation. B.P.F. Rutten is funded by a VIDI award (no. 91.718.336) from the Netherlands Scientific Organization. H. L. Fisher, C. Gayer-Anderson, and C. Morgan are supported by the Economic and Social Research Council (ESRC) Centre for Society and Mental Health at King’s College London [ES/S012567/1]. D. Quattrone is supported by the Medical Research Council Clinical Academic Research Partnership [MR/W030608/1]. M. Aas is supported by an MRC fellowship (#MR/WO27720/1). C. Arango has received support from the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, financed by the European Union—NextGenerationEU (PMP21/00051, PI19/01024), CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (Project FEP-CAUSAL), Fundación Familia Alonso, and Fundación Alicia Koplowitz. The views expressed are those of the authors and not necessarily those of the ESRC or King’s College London. Publisher Copyright: © 2023, The Author(s).
(Peer reviewed)